Drugs / Pamapimod
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05659459 | Aug 2022 → Oct 2023 | COVID-19 | Kinarus AG | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-01-17 | Kinarus AG | Results Kinarus Therapeutics Reports Preclinical Data in Lung Fibrosis and Discloses Clinical Development Plan kinarus.com ↗
In a mouse model of lung injury, KIN001 significantly reduced lung weights and tissue fibrosis score vs. controls. |
| 2022-09-30 | Kinarus AG | Results Kinarus Therapeutics Announces Discontinuation of the Phase 2 KINETIC Study of KIN001 in Hospitalized COVID-19 Patients Following a Prespecified Interim Analysis of Efficacy and Safety kinarus.com ↗
It therefore recommends that the KINETIC study be discontinued. |
All press releases naming this drug 2 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pamapimod | “Combination Pamapimod 75mg with Pioglitazone 5mg” NCT05659459 ↗ |
| Known as | R-1503 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1090089 ↗ |
| Known as | RO 4402257 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1090089 ↗ |
| Action | Inhibit | “MAP kinase p38 alpha inhibitor” CHEMBL1090089 ↗ |
| Modality | Small molecule | — CHEMBL1090089 ↗ |
| Route | Oral | “Oral tablet” NCT05659459 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL1090089 ↗ |